Schering Affiliate Gets OK for Rosacea Drug
- Share via
From Bloomberg News
Schering’s U.S. affiliate Berlex Laboratories won Food and Drug Administration approval to sell the gel Finacea for the skin condition rosacea, expanding the product line of the world’s biggest maker of contraceptive pills.
The gel will be available in the U.S. before the end of March, Schering said, adding that peak annual U.S. sales may reach $30 million. About 14 million people in the U.S. have rosacea.
Schering shares rose $1.20, or 2.8%, to $44.10 on the NYSE.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
